2019
Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
Warth B, Palermo A, Rattray NJW, Lee NV, Zhu Z, Hoang LT, Cai Y, Mazurek A, Dann S, VanArsdale T, Fantin VR, Shields D, Siuzdak G, Johnson CH. Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells. Metabolites 2019, 9: 7. PMID: 30609717, PMCID: PMC6359333, DOI: 10.3390/metabo9010007.Peer-Reviewed Original ResearchProgression-free survivalBreast cancer cell metabolismEstrogen receptor antagonistCyclin-dependent kinase 4Breast cancer cellsCancer cell metabolismCombination chemotherapyMCF-7 cellsReceptor antagonistCombination chemotherapeuticsSurvival advantageSelective metabolic pathwaysMetabolic disruptionCancer cellsMetabolic pathwaysKinase 4Cancer metabolismSelective inhibitorPalbociclibSame metabolic pathwayDrugsMetabolismTranscriptomic changesCell modelCell metabolism
2018
Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy
Warth B, Raffeiner P, Granados A, Huan T, Fang M, Forsberg EM, Benton HP, Goetz L, Johnson CH, Siuzdak G. Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. Cell Chemical Biology 2018, 25: 291-300.e3. PMID: 29337187, PMCID: PMC5856613, DOI: 10.1016/j.chembiol.2017.12.010.Peer-Reviewed Original ResearchConceptsEffects of palbociclibPositive breast cancerUS FDA approvalGlobal metabolomics approachMCF-7 cellsCombination therapyBreast cancerEstrogen receptorMetabolic effectsPhytoestrogen genisteinFDA approvalModel xenoestrogenCellular metabolismCancer therapyFunctional assaysXenoestrogensPathway modificationTherapyMetabolomics approachCombination cancer therapyFatty acidsEstrogenic mycotoxin zearalenoneProliferation experimentsMetabolitesMetabolism